Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | BioAtla reports promising trial results for cancer drug | 4 | Investing.com | ||
16.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.05. | BioAtla stock holds $1 target, JMP affirms Market Outperform | 2 | Investing.com | ||
06.05. | BioAtla files to sell 9.68M shares of common stock for holders | 3 | Seeking Alpha | ||
BIOATLA Aktie jetzt für 0€ handeln | |||||
06.05. | BioAtla, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
06.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.05. | A Preview Of BioAtla's Earnings | 3 | Benzinga.com | ||
24.04. | BioAtla, Inc.: BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
23.04. | BioAtla, Inc.: BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | 2 | GlobeNewswire (USA) | ||
21.04. | BioAtla stock holds $1 target, Market Outperform rating | 3 | Investing.com | ||
31.03. | BioAtla stock price target cut to $1 by Citizens JMP | 2 | Investing.com | ||
28.03. | BioAtla stock price target cut to $10 at BTIG, retains Buy rating | 4 | Investing.com | ||
28.03. | BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody | 1 | FierceBiotech | ||
27.03. | BioAtla announces 30% workforce reduction | 3 | Seeking Alpha | ||
27.03. | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | 177 | GlobeNewswire (Europe) | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen | |
27.03. | BioAtla, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
26.03. | Earnings Outlook For BioAtla | 4 | Benzinga.com | ||
20.03. | BioAtla, Inc.: BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings | 2 | GlobeNewswire (USA) | ||
19.03. | BioAtla, Inc.: BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 | 1 | GlobeNewswire (USA) | ||
14.03. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
BB BIOTECH | 32,850 | +0,77 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, INC. - 10-K, Annual Report | ||
INOVIO PHARMACEUTICALS | 1,980 | -0,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,917 | -0,97 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
INFLARX | 0,750 | +2,46 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIO-GATE | 1,050 | 0,00 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
BURCON NUTRASCIENCE | 0,073 | +5,80 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen |